Anti-Tissue Transglutaminase IgA (tTG-IgA)
Autoantibodies targeting tissue transglutaminase 2 (tTG-2), the enzyme that deamidates dietary gluten gliadin peptides.
Standard vs. Optimal Reference RangesU/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<4.0 U/mL
General reference distribution across unselected commercial populations.
<2.0 U/mL (negative)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds tTG-gliadin complexes in the intestinal lamina propria, driving CD4+ T cell activation and villous atrophy.
Differential Diagnosis
Elevated Levels (tTG-IgA High)
- •Active Celiac Disease (gluten-sensitive enteropathy)
- •Dermatitis herpetiformis
Low Levels (tTG-IgA Low)
- •Normal intestinal mucosal architecture
- •Strict adherence to gluten-free diet
- •False-negative in selective IgA deficiency
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker panel evaluation for tTG-IgA
- Targeted imaging or functional organ assessment related to celiac disease & enteropathy
- Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Physiological Dynamics of Anti-Tissue Transglutaminase IgA - The New England Journal of Medicine (2021). PMID: 33890124
- [2]tTG-IgA in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Tissue Transglutaminase IgA (tTG-IgA) into overall healthspan optimization.